<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467428</url>
  </required_header>
  <id_info>
    <org_study_id>NS2359-001</org_study_id>
    <nct_id>NCT00467428</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder</brief_title>
  <official_title>Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder. A Randomised, Double-Blind, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroSearch A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroSearch A/S</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate if NS2359 is effective in the treatment of ADHD in&#xD;
      adult patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the efficacy of NS2359 in adult patients diagnosed with ADHD (predominantly inattentive, predominantly hyperactive/impulsive or combined) according to DSM-IV criteria.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety and tolerability of NS2359 in adult ADHD patients.</measure>
  </secondary_outcome>
  <enrollment type="Actual">126</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NS2359</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), by&#xD;
             DSM-IV, as manifested in clinical evaluation and confirmed by structured interview&#xD;
             using the K-SADS-E adult ADHD module&#xD;
&#xD;
          -  Patients with a CGI Global Severity (GS) score â‰¥4 (moderate impairment)&#xD;
&#xD;
          -  The Patient provided written informed consent.&#xD;
&#xD;
          -  Non-lactating women of childbearing potential that used adequate contraception (i.e.&#xD;
             the use of oral contraceptives and practising a double-barrier form of birth control)&#xD;
             and had a negative pregnancy test at screening. Women of no childbearing potential who&#xD;
             had been postmenopausal for less than 2 years must have a negative pregnancy test at&#xD;
             screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically unstable medical condition&#xD;
&#xD;
          -  Clinically significant abnormal baseline laboratory values&#xD;
&#xD;
          -  Mental retardation&#xD;
&#xD;
          -  Organic brain disorders&#xD;
&#xD;
          -  Non-febrile seizure disorder&#xD;
&#xD;
          -  Patients with a history of an eating disorder including anorexia or bulimia nervosa&#xD;
&#xD;
          -  Psychotic disorder of any type&#xD;
&#xD;
          -  Patients with a HAM-D (17 item) &gt;15&#xD;
&#xD;
          -  Patients currently (within the past 6 months) known to abuse or to be dependent on any&#xD;
             drug, including alcohol or a positive urine drug screen for cocaine, heroin, or&#xD;
             marijuana&#xD;
&#xD;
          -  Treatment with stimulants was prohibited within 1 week prior to randomisation&#xD;
&#xD;
          -  Treatment with antipsychotics/neuroleptics was prohibited for 8 weeks prior to&#xD;
             randomisation&#xD;
&#xD;
          -  Treatment with monoamine oxidase inhibitors was prohibited for 8 weeks prior to&#xD;
             randomisation&#xD;
&#xD;
          -  Treatment with tricyclic antidepressants, histamines and selective serotonin reuptake&#xD;
             inhibitors was prohibited for 4 weeks (fluoxetine for 6 weeks) prior to randomisation&#xD;
&#xD;
          -  Treatment with benzodiazepines, anticonvulsants (for behaviour) and lithium for 2&#xD;
             weeks prior to randomisation&#xD;
&#xD;
          -  Patients with a history of bipolar disorder&#xD;
&#xD;
          -  Patients using any concurrent medication for the treatment of ADHD&#xD;
&#xD;
          -  Patients that had previously participated in a NS2359 study&#xD;
&#xD;
          -  Patients treated with an investigational drug within 30 days or 5 half-lives&#xD;
             (whichever is longer) preceding the first dose of study medication&#xD;
&#xD;
          -  Patients with a history of positive human immunodeficiency virus (HIV) test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thimothy Wilens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adult and Pediatric Psychopharmacology, Masschusetts General Hospial, Boston, US</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adult and Pediatric Psychopharmacology, Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 27, 2007</study_first_submitted>
  <study_first_submitted_qc>April 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2007</study_first_posted>
  <last_update_submitted>April 27, 2007</last_update_submitted>
  <last_update_submitted_qc>April 27, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2007</last_update_posted>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

